Table 2 Comparison of the epidemiological characteristics for patients received crizotinib treatment
Characteristics | Group | P value | |||
|---|---|---|---|---|---|
Total | 1-CRZ | 1-PP | N1-PP | ||
Total, n | 65 | 31 | 22 | 12 | |
Gender, n (%) | |||||
Male | 31 (47.7) | 18 (58.1) | 8 (36.4) | 5 (41.7) | 0.267 |
Female | 34 (52.3) | 13 (41.9) | 14 (63.6) | 7 (58.3) | |
Median age, year (range) | 50.2 (23–73) | 50.9 (30–73) | 51.9 (23–71) | 42.5 (23–61) | 0.640 |
Smoking, n (%) | |||||
Never | 44 (67.7) | 19 (61.3) | 17 (77.3) | 8 (66.7) | 0.470 |
Current/Former | 21 (32.3) | 12 (38.7) | 5 (22.7) | 4 (33.3) | |
ECOG score, n (%) | |||||
0 or 1 | 55 (84.6) | 29 (93.5) | 18 (81.8) | 8 (66.7) | 0.035 |
> = 2 | 10 (15.4) | 2 (6.5) | 4 (18.2) | 4 (33.3) | |
Extent of disease, n (%) | |||||
Locally advanced | 10 (15.4) | 5 (16.1) | 3 (13.6) | 2 (16.7) | 0.961 |
Metastatic | 55 (84.6) | 26 (83.9) | 19 (86.4) | 10 (83.3) | |